niacinamide has been researched along with Thymoma in 10 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Thymoma: A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present studies were undertaken to determine whether the multikinase inhibitors sorafenib/regorafenib cooperated with clinically relevant , phosphatidyl inositol 3 kinase (PI3K)-thymoma viral proto-oncogene (AKT) inhibitors to kill tumor cells." | 7.79 | Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. ( Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S, 2013) |
| "The present studies were undertaken to determine whether the multikinase inhibitors sorafenib/regorafenib cooperated with clinically relevant , phosphatidyl inositol 3 kinase (PI3K)-thymoma viral proto-oncogene (AKT) inhibitors to kill tumor cells." | 3.79 | Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. ( Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S, 2013) |
| "Thymoma and thymic carcinoma are rare neoplasms of the mediastinum, arising from the epithelial cells of the thymus." | 1.38 | Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma. ( Luyken, J; Neuhaus, T, 2012) |
| "Metastatic thymic carcinoma is an aggressive neoplasm for which multimodal therapies are often ineffective." | 1.35 | Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. ( Bisagni, G; Boni, C; Cavazza, A; Gardini, G; Rossi, G; Sartori, G, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sajithlal, GB | 1 |
| Hamed, HA | 1 |
| Cruickshanks, N | 1 |
| Booth, L | 1 |
| Tavallai, S | 1 |
| Syed, J | 1 |
| Grant, S | 1 |
| Poklepovic, A | 1 |
| Dent, P | 1 |
| Pagano, M | 1 |
| Sierra, NM | 1 |
| Panebianco, M | 1 |
| Rossi, G | 3 |
| Gnoni, R | 1 |
| Bisagni, G | 2 |
| Boni, C | 2 |
| Bolzacchini, E | 1 |
| Chini, C | 1 |
| Pinotti, G | 1 |
| Azad, A | 1 |
| Herbertson, RA | 1 |
| Pook, D | 1 |
| White, S | 1 |
| Mitchell, PL | 1 |
| Tebbutt, NC | 1 |
| Cavazza, A | 2 |
| Sartori, G | 2 |
| Gardini, G | 1 |
| Force, J | 1 |
| Rajan, A | 1 |
| Dombi, E | 1 |
| Steinberg, SM | 1 |
| Giaccone, G | 1 |
| Schirosi, L | 1 |
| Nannini, N | 1 |
| Nicoli, D | 1 |
| Valli, R | 1 |
| Buti, S | 1 |
| Garagnani, L | 1 |
| Calabrese, F | 1 |
| Marchetti, A | 1 |
| Buttitta, F | 1 |
| Felicioni, L | 1 |
| Migaldi, M | 1 |
| Rea, F | 1 |
| Di Chiara, F | 1 |
| Mengoli, MC | 1 |
| Neuhaus, T | 1 |
| Luyken, J | 1 |
| Bartoli, GM | 1 |
| Piccioni, E | 1 |
| Agostara, G | 1 |
| Calviello, G | 1 |
| Palozza, P | 1 |
| Fishman, M | 1 |
| Essani, N | 1 |
| Costlow, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort[NCT03921671] | Phase 2 | 60 participants (Anticipated) | Interventional | 2018-11-01 | Recruiting | ||
| Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)[NCT03449173] | Phase 2 | 56 participants (Anticipated) | Interventional | 2017-03-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for niacinamide and Thymoma
| Article | Year |
|---|---|
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large | 2011 |
9 other studies available for niacinamide and Thymoma
| Article | Year |
|---|---|
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
Topics: Animals; Cell Communication; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Gonanes; Hep G2 C | 2013 |
Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
Topics: Aged; Antineoplastic Agents; DNA Mutational Analysis; Female; Humans; Male; Middle Aged; Mutation; N | 2014 |
Response of Malignant Thymoma to Sorafenib.
Topics: Adult; Antineoplastic Agents; Female; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Thymoma; | 2016 |
Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma.
Topics: Administration, Oral; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.
Topics: Base Sequence; Benzenesulfonates; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation, Miss | 2009 |
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Benzenesulfonates; Carcinoid Tumo | 2012 |
Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.
Topics: Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged | 2012 |
Different mechanisms of tert-butyl hydroperoxide-induced lethal injury in normal and tumor thymocytes.
Topics: Adenosine Triphosphate; Animals; Cell Compartmentation; Cell Survival; Cells, Cultured; Cytosol; Def | 1994 |
TPA induction of EL4 resistance to macrophage-released TNF: role of ADP-ribosylation in tumoricidal activities of TNF and other factors.
Topics: Animals; Antibodies; Benzamides; Calcimycin; Cytotoxicity, Immunologic; Cytotoxins; Down-Regulation; | 1990 |